MLPH Stock Overview
Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Molecular Pharmacology (USA), Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.005 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -99.00% |
| 3 Month Change | -99.88% |
| 1 Year Change | -99.00% |
| 33 Year Change | n/a |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MLPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -99.0% | 2.6% | 0.5% |
| 1Y | -99.0% | 13.1% | 30.7% |
Return vs Industry: MLPH underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: MLPH underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| MLPH volatility | |
|---|---|
| MLPH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MLPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jeff Edwards | n/a |
Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain.
Molecular Pharmacology (USA), Ltd. Fundamentals Summary
| MLPH fundamental statistics | |
|---|---|
| Market cap | US$999.00 |
| Earnings (TTM) | -US$105.18k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$105.18k |
| Earnings | -US$105.18k |
Last Reported Earnings
Sep 30, 2014
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MLPH perform over the long term?
See historical performance and comparison